



ADVISED
ABL DIAGNOSTICS (EX ETABLISSEMENTS FAUVET-GIREL)
IN THE CONTEXT OF A MERGER WITH ABL FRANCE

September 2022



ABL DIAGNOSTICS develops, manufactures and markets molecular detection diagnostic test kits and DNA sequencing genotyping tests targeting chronic infectious diseases. ABL DIAGNOSTICS has developed high-tech genotyping products for AIDS and viral hepatitis. ABL DIAGNOSTICS is also developing products for the genotyping of SARS-CoV-2 (COVID-19), tuberculosis and other viral and bacterial targets.

The activities carried out by ABL DIAGNOSTICS are conducted from its headquarters in Metz with 2 laboratories. In addition, the manufacturing of components in the tubes of diagnostic test kits is carried out in the laboratory in Marseille. Finally, an office located in Paris is dedicated to tertiary functions.

ABL DIAGNOSTICS relied on a team of about twenty employees.

ATOUCAPITAL advised the shareholders of ABL DIAGNOSTICS in the context of an RTO (Reverse Take-Over) merger using the listed structure ABL DIAGNOSTICS, formerly known as ETABLISSEMENTS FAUVET-GIREL.

This merger of ABL FRANCE into ABL DIAGNOSTICS was approved by the AMF on July 12, 2022 and approved by the shareholders at the General Meeting held on August 3, 2022.

With a valuation of approximately €28 million retained for ABL FRANCE, this activity of development and marketing of diagnostic kits is now housed in the structure ABL DIAGNOSTICS whose shares are admitted to trading on compartment C of Euronext Paris (ISIN FRO01400AHX6 - Mnémo ABLD) and could soon call on the market to finance the acceleration of its development.